Dipalmitoyl-DL-α-glycerylphosphorylpropanol | 107862-69-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: Dipalmitoyl-DL-α-glycerylphosphorylpropanol
• 英文别名: [2-Hexadecanoyloxy-3-[hydroxy(propoxy)phosphoryl]oxypropyl] hexadecanoate
• CAS: 107862-69-1
• 化学式: C₃₈H₇₅O₈P
• 分子量: 690.982
• InChiKey: RCMFJAOFQVNWNI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  14.4
• 重原子数：
  47
• 可旋转键数：
  39
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  Dipalmitoyl-DL-α-glycerylphosphorsaeure-benzylester 在 sodium iodide 作用下， 以 丙酮 为溶剂， 生成 Dipalmitoyl-DL-α-glycerylphosphorylpropanol
  参考文献：
  名称：

  On the Cardiolipin Analogues. Syntheses of Dipalmitoyl-D, L-α-glycerylphosphoryl-propanol Sodium Salt and Bis (dipalmitoyl-D, L-α-glyceryl-phosphoryl)-1, 3-propanediol Disodium Salt.

  摘要：

  双（二棕榈酰-D，L-α-甘油磷酰）丙醇钠盐（I）和双（二棕榈酰-D，L-α-甘油磷酰）-1,3-丙二醇二钠盐（II）是通过将二棕榈酰-D，L-α-甘油磷酸苄酯的银盐（III）与烷基碘进行缩合，随后用碘化钠脱苄基合成的。研究发现，II在硅胶柱上转化为酸形式。

  DOI：

  10.1248/cpb.11.1150

文献信息

• TARGETING MICROBUBBLES
  申请人：CALIFORNIA INSTITUTE OF TECHNOLOGY

  公开号：US20160367669A1

  公开（公告）日：2016-12-22

  This invention related to manufactured microbubbles, as well as methods of using manufactured microbubbles, for example, in medicinal applications. The invention pertains to the physical structure and materials of the microbubbles, as well as to methods for manufacturing microbubbles, methods for targeting microbubbles for specific medicinal applications, and methods for delivering microbubbles in medical treatment.

  这项发明涉及制造微泡，以及使用制造的微泡的方法，例如在药用应用中。该发明涉及微泡的物理结构和材料，以及制造微泡的方法，将微泡定位到特定药用应用的方法，以及在医疗治疗中输送微泡的方法。
• Compounds and Compositions for Nucleic Acid Formulation and Delivery
  申请人：Boylan John Frederick

  公开号：US20130072543A1

  公开（公告）日：2013-03-21

  The invention relates to compositions containing compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R, R 1 , R 2 , R 3 , and n are defined in the detailed description and claims. In addition, the present invention relates to novel formulations containing compounds of formula I for improved delivery of nucleic acids such as siRNA to the cytoplasm of target cells. In particular embodiments these formulations comprise compounds of formula I, phospholipids, cholesterol, and pegylated lipids. The present invention also relates to methods of manufacturing and using such compounds and compositions.

  本发明涉及含有公式I化合物的组合物及其药学上可接受的盐，其中R、R1、R2、R3和n在详细描述和权利要求中定义。此外，本发明涉及新的公式I化合物的制剂，用于改善核酸如siRNA输送至靶细胞的细胞质。在特定实施例中，这些制剂包括公式I化合物、磷脂、胆固醇和聚乙二醇化脂质。本发明还涉及制备和使用这些化合物和组合物的方法。
• Investigation of insulin-containing liposomes from an equimolar mixture of dipalmitoylphos-phatidylcholine and dipalmitoylphosphatidylethanol as a peroral drug form
  作者：A. A. Akhrem、A. P. Vlasov、M. S. Vorob'ev、Z. V. Zaborovskaya、M. A. Kisel、E. V. Kholodova、I. S. Tsybovskii

  DOI：10.1007/bf02219306

  日期：1994.10
• Orally Bioavailable Lipid-Based Constructs
  申请人：SDG, Inc.

  公开号：US20130183270A1

  公开（公告）日：2013-07-18

  The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapetuic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.
• Lipid Construct for Delivery of Insulin to a Mammal
  申请人：SDG, INC.

  公开号：US20130267462A1

  公开（公告）日：2013-10-10

  The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.